Scott T. Aaronson, MD is the Chief Science Officer for the Institute for Advanced Diagnostics and Therapeutics at Sheppard Pratt. In this 5 Minute Pearls video, he shares clinically relevant insights at the intersection of psychiatry and psychedelics.
“We’re at the cusp of a revolution in psychiatry.” He calls it a “metamorphosis” led by psychedelics and MDMA.
Psychedelics appear to work mostly as a serotonin agonist that cause a mind-altering state that quickly ramp up neuronal connectivity and neuronal plasticity.
Psychedelics show therapeutic benefit for myriad psychiatric conditions, including depression, OCD, trauma, addiction, eating disorders, and perhaps autism. It is not likely to benefit bipolar or psychotic disorders.....more
Comments